Koen Van Besien to Mutation
This is a "connection" page, showing publications Koen Van Besien has written about Mutation.
Connection Strength
0.125
-
Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation. Leuk Lymphoma. 2019 07; 60(7):1626-1631.
Score: 0.071
-
Chronic myelogenous leukemia: role of stem cell transplant in the imatinib era. Hematol Oncol Clin North Am. 2011 Oct; 25(5):1025-48, vi.
Score: 0.042
-
Identifying familial myelodysplastic/acute leukemia predisposition syndromes through hematopoietic stem cell transplantation donors with thrombocytopenia. Blood. 2012 Dec 20; 120(26):5247-9.
Score: 0.012